Please assess the completion status of the following clinical trial:

Trial Title: Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA~* The study population will comprise individuals who have transfusion-dependent hemolytic PNH.~* Each patient must meet the following criteria to be enrolled in this study:~  1. Individuals at least 18 years of age~ 2. Patients with a diagnosis of PNH greater than 6 months~ 3. Presence of a GPI deficient red blood cell clone (type III cells) by flow cytometry of greater than or equal to 10%~ 4. Patients must have: at least one transfusion in the past two years for anemia or anemia-related symptoms -or personal beliefs that preclude the use of transfusion, with severe hemolytic PNH~ 5. Documented LDH level greater than or equal to 1.5 x upper limit of normal (ULN) within 12 weeks of Visit 1 or during the Screening Period~ 6. Patient must be willing and able to give written informed consent.~ 7. Patients must avoid conception during the trial using a method that is most appropriate for their physical state and culture.~* Subjects must have a Visa allowing stay in United States for the duration of the study (up to 3 years).~* Subjects must provide documentation of residence during stay in the United States.~* The subject must be willing to keep all visits and not travel outside of the country while being treated under the protocol.~* The subject must understand that the drug may not be made commercially available in their country.~* Once the protocol and extension study is complete, the subject must come off study medication and it will not be made available to them if they return to their country.~EXCLUSION CRITERIA~-Any patient meeting any of the following criteria will be excluded from the study:~1. Platelet count of less than 30,000/mm3~2. Absolute Neutrophil count less than or equal to 500/uL~3. Presence or suspicion of active bacterial infection, in the opinion of the Investigator, at Visit 2 or recurrent bacterial infections~4. Known or suspected hereditary complement deficiency~5. History of bone marrow transplantation~6. Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedure within 30 days prior to screening~7. Pregnant, breast-feeding, or intending to conceive during the course of the study,including the Safety Follow-up Visits~8 .History of meningococcal disease~9. Patients who are not vaccinated against N. meningitidis at least 14 days prior to Visit 2~10. Any condition that, in the opinion of the Investigator, could increase the patient's risk by participating in the study or confound the outcome of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).